0001415889-24-011064.txt : 20240417
0001415889-24-011064.hdr.sgml : 20240417
20240417202117
ACCESSION NUMBER: 0001415889-24-011064
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240415
FILED AS OF DATE: 20240417
DATE AS OF CHANGE: 20240417
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Syntone Ventures LLC
CENTRAL INDEX KEY: 0001814394
ORGANIZATION NAME:
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37759
FILM NUMBER: 24852555
BUSINESS ADDRESS:
STREET 1: 1517 CHAMPLAIN CREST WAY
CITY: CARY
STATE: NC
ZIP: 27513
BUSINESS PHONE: 781-308-0823
MAIL ADDRESS:
STREET 1: 1517 CHAMPLAIN CREST WAY
CITY: CARY
STATE: NC
ZIP: 27513
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Outlook Therapeutics, Inc.
CENTRAL INDEX KEY: 0001649989
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 383982704
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0930
BUSINESS ADDRESS:
STREET 1: 485 ROUTE 1 SOUTH
STREET 2: BUILDING F, SUITE 320
CITY: ISELIN
STATE: NJ
ZIP: 08830
BUSINESS PHONE: 6096193990
MAIL ADDRESS:
STREET 1: 485 ROUTE 1 SOUTH
STREET 2: BUILDING F, SUITE 320
CITY: ISELIN
STATE: NJ
ZIP: 08830
FORMER COMPANY:
FORMER CONFORMED NAME: Oncobiologics, Inc.
DATE OF NAME CHANGE: 20150804
4
1
form4-04182024_120410.xml
X0508
4
2024-04-15
0001649989
Outlook Therapeutics, Inc.
OTLK
0001814394
Syntone Ventures LLC
1517 CHAMPLAIN CREST WAY
CARY
NC
27513
false
false
true
false
0
Common Stock
2024-04-15
4
P
0
714286
A
1705438
D
Warrant (Right to Buy)
7.70
2024-04-15
4
P
0
1071429
A
2024-04-15
2029-04-15
Common Stock
1071429
1071429
D
Acquired in a private placement transaction pursuant to the terms of the Securities Purchase Agreement (the "SPA"), dated as of January 22, 2024, between Outlook Therapeutics, Inc. (the "Issuer") and Syntone Ventures LLC ("Syntone"), pursuant to which the Issuer sold shares of common stock, and, for each such share of common stock, accompanying warrants to purchase up to one and a half shares of common stock, at a purchase price of $7.00 per share and accompanying warrant. Under the SPA, Syntone purchased 714,286 shares of common stock and warrants to acquire 1,071,429 shares of common stock closed on April 15, 2024.
Effective March 14, 2024, every 20 issued and outstanding shares of the Issuer's common stock was automatically combined into one issued and outstanding share of the Issuer's common stock (the "Reverse Stock Split"). Prior to the Reverse Stock Split, Syntone held 19,823,045 shares of common stock and, as a result of the Reverse Stock Split, such shares of common stock became 991,152 shares of common stock.
/s/ Jiahui Zheng, Attorney-in-Fact
2024-04-17